In the six months after joining Arena Pharmaceuticals Inc. as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq (lorcaserin), which it has partnered with Eisai Co. Ltd.; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?